Cargando…

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients

As a crucial cell cycle regulator and G2/M phase promotor, CCNB1 played an essential role in progression of chemotherapy related cell death. Platinum-based chemotherapy is still the first-line chemotherapy regimen for most advanced NSCLC patients. We aim to investigate the correlation of CCNB1 polym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Di, Xu, Wen, Ding, Xi, Yang, Yang, Su, Bo, Fei, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688932/ https://www.ncbi.nlm.nih.gov/pubmed/29151966 http://dx.doi.org/10.7150/jca.21151

Ejemplares similares

CCNB1 and CCNB2 involvement in the pathogenesis of psoriasis: a bioinformatics study
por: Li, An-hai, et al.
Publicado: (2022)

Variations within 3′-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy
por: Yang, Yang, et al.
Publicado: (2016)

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC
por: WANG, YA-DI, et al.
Publicado: (2011)

Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
por: Soon, Yu Yang, et al.
Publicado: (2023)

Requirement for CCNB1 in mouse spermatogenesis
por: Tang, Ji-Xin, et al.
Publicado: (2017)

XRCC3 Thr241Met Polymorphism and Clinical Outcomes of NSCLC Patients Receiving Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
por: Shen, Xiao-yong, et al.
Publicado: (2013)

Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement
por: Li, Dan-Juan, et al.
Publicado: (2017)

CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma
por: Zou, Yiping, et al.
Publicado: (2020)

Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients
por: Wu, Wenting, et al.
Publicado: (2012)

CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer
por: Wang, Xue-Xuan, et al.
Publicado: (2023)

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy
por: Xue, Ping, et al.
Publicado: (2022)

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC
por: Xian, Sun, et al.
Publicado: (2014)

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
por: Nishio, Makoto, et al.
Publicado: (2021)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC
por: Zhou, Hongxuan, et al.
Publicado: (2016)

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients
por: Liu, Di, et al.
Publicado: (2015)

Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1
por: Lin, Zhenghong, et al.
Publicado: (2015)

Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
por: Hayashi, Hidetoshi, et al.
Publicado: (2023)

Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review
por: Afifah, Nadiya Nurul, et al.
Publicado: (2020)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

Effect of XPC polymorphisms on the response to platinum-based chemotherapy: a meta-analysis
por: Xie, Chenyao, et al.
Publicado: (2019)

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
por: Xu, Meizhen, et al.
Publicado: (2017)

Establishing a Prediction Model for the Efficacy of Platinum—Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study
por: Xiao, Qi, et al.
Publicado: (2023)

Rare Case of BCOR::CCNB3 Sarcoma of Bone
por: Arai, Yumi, et al.
Publicado: (2023)

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy
por: Kusuhara, Seiichiro, et al.
Publicado: (2021)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth
por: Shi, Qiong, et al.
Publicado: (2016)

Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies
por: Qin, Qin, et al.
Publicado: (2013)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

BCOR-CCNB3 sarcoma with concurrent RNF213-SLC26A11 gene fusion: a rare sarcoma with altered histopathological features after chemotherapy
por: Huang, Wen, et al.
Publicado: (2022)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

CCNB2 as a potential biomarker of bladder cancer via the high throughput technology
por: Zhang, Lei, et al.
Publicado: (2023)

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients
por: Gu, Weiguang, et al.
Publicado: (2023)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
por: Jiang, Tao, et al.
Publicado: (2017)

HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis
por: Chen, Er-Bao, et al.
Publicado: (2019)

Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population
por: Liu, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0gkiumdhru1id1gcbm1qcfpo78